{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:52:04Z","timestamp":1788648724042,"version":"build-2803163510"},"reference-count":211,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Phosphorus is one of the most abundant minerals in the body and plays a critical role in numerous cellular and metabolic processes. Most of the phosphate is deposited in bones, 14% is present in soft tissues as various organic phosphates, and only 1% is found in extracellular space, mainly as inorganic phosphate. The plasma inorganic phosphate concentration is closely maintained between 2.5 and 4.5 mg\/dL by intertwined interactions between fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), and vitamin D, which tightly regulate the phosphate trafficking across the gastrointestinal tract, kidneys, and bones. Disruption of the strict hemostatic control of phosphate balance can lead to altered cellular and organ functions that are associated with high morbidity and mortality. In the past three decades, there has been a steady increase in the prevalence of kidney failure (KF) among populations. Individuals with KF have unacceptably high mortality, and well over half of deaths are related to cardiovascular disease. Abnormal phosphate metabolism is one of the major factors that is independently associated with vascular calcification and cardiovascular mortality in KF. In early stages of CKD, adaptive processes involving FGF-23, PTH, and vitamin D occur in response to dietary phosphate load to maintain plasma phosphate level in the normal range. However, as the CKD progresses, these adaptive events are unable to overcome phosphate retention from continued dietary phosphate intake and overt hyperphosphatemia ensues. As these hormonal imbalances and the associated adverse consequences are driven by the underlying hyperphosphatemic state in KF, it appears logical to strictly control serum phosphate. Conventional dialysis is inadequate in removing phosphate and most patients require dietary restrictions and pharmacologic interventions to manage hyperphosphatemia. However, diet control comes with many challenges with adherence and may place patients at risk for inadequate protein intake and malnutrition. Phosphate binders help to reduce phosphate levels but come with a sizable pill burden and high financial costs and are associated with poor adherence and psychosocial issues. Additionally, long-term use of binders may increase the risk of calcium, lanthanum, or iron overload or promote gastrointestinal side effects that exacerbate malnutrition and affect quality of life. Given the aforesaid challenges with phosphorus binders, novel therapies targeting small intestinal phosphate absorption pathways have been investigated. Recently, tenapanor, an agent that blocks paracellular absorption of phosphate via inhibition of enteric sodium\u2013hydrogen exchanger-3 (NHE3) was approved for the treatment of hyperphosphatemia in KF. While various clinical tools are now available to manage hyperphosphatemia, there is a lack of convincing clinical data to demonstrate improvement in outcomes in KF with the lowering of phosphorus level. Conceivably, deleterious effects associated with hyperphosphatemia could be attributable to disruptions in phosphorus-sensing mechanisms and hormonal imbalance thereof. Further exploration of mechanisms that precisely control phosphorus sensing and regulation may facilitate development of strategies to diminish the deleterious effects of phosphorus load and improve overall outcomes in KF.<\/jats:p>","DOI":"10.3390\/nu17091587","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T21:42:09Z","timestamp":1746481329000},"page":"1587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management"],"prefix":"10.3390","volume":"17","author":[{"given":"Swetha","family":"Raju","sequence":"first","affiliation":[{"name":"Division of Nephrology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-9509","authenticated-orcid":false,"given":"Ramesh","family":"Saxena","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Erdman, J.W., Macdonald, I.A., and Zeisel, S.H. (2012). Phosphorus. Present Knowledge in Nutrition, Wiley-Blackwell. [10th ed.].","DOI":"10.1002\/9781119946045"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-030-91623-7_7","article-title":"Phosphate and Cellular Senescence","volume":"1362","author":"Hu","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_3","unstructured":"Phosphorus (2025, March 24). Facts Sheet for Health Professionals, Available online: https:\/\/ods.od.nih.gov\/factsheets\/Phosphorus-HealthProfessional\/#en1."},{"key":"ref_4","unstructured":"(2025, March 24). The United States Renal Data System Annual Data Report 2024, Available online: https:\/\/usrds-adr.niddk.nih.gov\/2024."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1681\/ASN.2011121191","article-title":"Mechanistic insights into vascular calcification in CKD","volume":"24","author":"Shroff","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","first-page":"E10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Shroff","year":"2000","journal-title":"Circ. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"F891","DOI":"10.1152\/ajprenal.00163.2014","article-title":"A current understanding of vascular calcification in CKD","volume":"307","author":"Paloian","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e164610","DOI":"10.1172\/JCI164610","article-title":"Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis","volume":"133","author":"Zhou","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.ackd.2010.11.004","article-title":"Intestinal phosphate transport","volume":"18","author":"Sabbagh","year":"2011","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Berndt, T.J., and Kumar, R. (2013). Clinical Disturbances of Phosphate Homeostasis. Seldin and Giebisch\u2019s the Kidney, Academic Press. [5th ed.].","DOI":"10.1016\/B978-0-12-381462-3.00069-0"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/cs0560407","article-title":"Absorption of inorganic phosphate in the human small intestine","volume":"56","author":"Walton","year":"1979","journal-title":"Clin. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00588690","article-title":"Unidirectional influx of phosphate across the mucosal membrane of rabbit small intestine","volume":"385","author":"Danisi","year":"1980","journal-title":"Pflugers Arch."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0016-5085(83)90443-2","article-title":"Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency","volume":"85","author":"Davis","year":"1983","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MNH.0b013e3283621310","article-title":"The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease","volume":"22","author":"Marks","year":"2013","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2009050559","article-title":"Intestinal npt2b plays a major role in phosphate absorption and homeostasis","volume":"20","author":"Sabbagh","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"F285","DOI":"10.1152\/ajprenal.00508.2009","article-title":"Phosphate homeostasis and the renal-gastrointestinal axis","volume":"299","author":"Marks","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ekir.2017.08.003","article-title":"NPT-IIb inhibition does not improve hyperphosphatemia in CKD","volume":"3","author":"Larsson","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/1535370219831220","article-title":"Intestinal phosphate absorption: The paracellular pathway predominates?","volume":"244","author":"Saurette","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"G233","DOI":"10.1152\/ajpgi.00032.2019","article-title":"Paracellular transport of phosphate along the intestine","volume":"317","author":"Himmerkus","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_22","first-page":"G90","article-title":"Phosphate transport across rat jejunum: Influence of sodium, pH, and 1,25-dihydroxyvitamin D3","volume":"251","author":"Lee","year":"1986","journal-title":"Am. J. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eaam6474","DOI":"10.1126\/scitranslmed.aam6474","article-title":"Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability","volume":"10","author":"King","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_24","first-page":"G483","article-title":"Intestinal distribution of human Na+\/H+ exchanger isoforms NHE-1, NHE-2, and NHE-3 mRNA","volume":"271","author":"Dudeja","year":"1996","journal-title":"Am. J. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-017-0614-0","article-title":"Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: Two trials in healthy volunteers","volume":"38","author":"Rosenbaum","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial","volume":"30","author":"Block","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-015-0705-z","article-title":"Regulation of renal phosphate handling: Inter-organ communication in health and disease","volume":"34","author":"Tatsumi","year":"2016","journal-title":"J. Bone Min. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MNH.0000000000000053","article-title":"Renal phosphate transporters","volume":"23","author":"Lederer","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Erben, R.G. (2018). Physiological Actions of Fibroblast Growth Factor-23. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00267"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MNH.0b013e32832c2264","article-title":"Parathyroid hormone signaling in bone and kidney","volume":"18","author":"Lee","year":"2009","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bargagli, M., Arena, M., Naticchia, A., Gambaro, G., Mazzaferro, S., Fuster, D., and Ferraro, P.M. (2021). The Role of Diet in Bone and Mineral Metabolism and Secondary Hyperparathyroidism. Nutrients, 13.","DOI":"10.3390\/nu13072328"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/er.2013-1079","article-title":"Molecular Basis of Klotho: From Gene to Function in Aging","volume":"36","author":"Xu","year":"2015","journal-title":"Endocrine Reviews"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41581-018-0078-3","article-title":"The Klotho proteins in health and disease","volume":"15","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Dalton, G.D., Xie, J., An, S.-w., and Huang, C.-L. (2017). New Insights into the Mechanism of Action of Soluble Klotho. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00323"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Buchanan, S., Combet, E., Stenvinkel, P., and Shiels, P.G. (2020). Klotho, Aging, and the Failing Kidney. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00560"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chen, K., and Sun, Z. (2021). Estrogen inhibits renal Na-Pi Co-transporters and improves klotho deficiency-induced acute heart failure. Redox Biol., 47.","DOI":"10.1016\/j.redox.2021.102173"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1124\/mol.109.055780","article-title":"Regulation of ROMK1 channel and renal K+ excretion by Klotho","volume":"76","author":"Cha","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.1114245","article-title":"The \u03b2-glucuronidase klotho hydrolyzes and activates the TRPV5 channel","volume":"310","author":"Chang","year":"2005","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"35849","DOI":"10.1074\/jbc.M114.616649","article-title":"Klotho up-regulates renal calcium channel transient receptor potential vanilloid 5 (TRPV5) by intra- and extracellular n-glycosylation-dependent mechanisms","volume":"289","author":"Wolf","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000082004","article-title":"Gross M-L Hyperphosphatemia in renal failure","volume":"23","author":"Ritz","year":"2005","journal-title":"Blood Purif."},{"key":"ref_42","unstructured":"Nissenson, A.R., and Fine, R.N.B.T. (2017). Chronic kidney disease\u2013mineral and bone disorder. Handbook of Dialysis Therapy, Elsevier. [5th ed.]."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archinte.167.9.879","article-title":"Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community","volume":"167","author":"Dhingra","year":"2007","journal-title":"Arch. Intern Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000443449","article-title":"Mortality and associated risk factors in dialysis patients with cardiovascular disease","volume":"41","author":"Tong","year":"2016","journal-title":"Kidney Blood Press Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"iii28","DOI":"10.1093\/ndt\/gfy174","article-title":"Cardiovascular disease in dialysis patients","volume":"33","author":"Cozzolino","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.02101205","article-title":"Association of disorders in mineral metabolism with progression of chronic kidney disease","volume":"1","author":"Schwartz","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca \u00d7 PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1681\/ASN.V12112511","article-title":"Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure","volume":"12","author":"Cozzolino","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1159\/000485874","article-title":"High phosphate-induced calcification of vascular smooth muscle cells is associated with the TLR4\/NF-\u03bab signaling pathway","volume":"42","author":"Zhang","year":"2017","journal-title":"Kidney Blood Press. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2215\/CJN.02120508","article-title":"Media Calcification and Intima Calcification Are Distinct Entities in Chronic Kidney Disease","volume":"3","author":"Amann","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/ki.2009.83","article-title":"Phosphate feeding induces arterial medial calcification in uremic mice: Role of serum phosphorus, fibroblast growth factor-23, and osteopontin","volume":"75","author":"Pai","year":"2009","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2010040349","article-title":"Matrix remodeling in vascular calcification associated with chronic kidney disease","volume":"21","author":"Pai","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1159\/000489144","article-title":"Fibulin-3 attenuates phosphate-induced vascular smooth muscle cell calcification by inhibition of oxidative stress","volume":"46","author":"Luong","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"ref_56","first-page":"2077","article-title":"Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia","volume":"76","author":"Voelkl","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/CIRCHEARTFAILURE.114.001272","article-title":"Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease","volume":"7","author":"Wannamethee","year":"2014","journal-title":"Circulation Heart Fail."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Vogt, I., Haffner, D., and Leifheit-Nestler, M. (2019). FGF23 and Phosphate\u2013Cardiovascular Toxins in CKD. Toxins, 11.","DOI":"10.3390\/toxins11110647"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)","volume":"60","author":"Ix","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41569-023-00903-0","article-title":"FGF23 and klotho at the intersection of kidney andcardiovascular disease","volume":"21","author":"Edmonston","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/08968608241231697","article-title":"Serum fibroblast growth factor 23 concentration and the risk of mortality in patients undergoing peritoneal dialysis","volume":"44","author":"Zhong","year":"2024","journal-title":"Perit. Dial. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"709024","DOI":"10.1155\/2014\/709024","article-title":"Association between parathyroid hormone levels and inflammatory markers among US adults","volume":"2014","author":"Cheng","year":"2014","journal-title":"Mediators Inflamm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0272-6386(96)90519-3","article-title":"Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: Further evidence implicating calcium homeostasis in blood pressure regulation","volume":"27","author":"Goldsmith","year":"1996","journal-title":"Am. J. Kidney Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.1988.252","article-title":"Fatty acid oxidation in the myocardium: Effects of parathyroid hormone and CRF","volume":"34","author":"Smogorzewski","year":"1988","journal-title":"Kidney Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000092244","article-title":"Effect of parathyroidectomy on cardiac fibrosis and apoptosis: Possible role of aldosterone","volume":"103","author":"Amato","year":"2006","journal-title":"Nephron Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.ehj.2003.09.010","article-title":"Parathyroid hormone and left ventricular hypertrophy","volume":"24","author":"Saleh","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4158\/EP14123.OR","article-title":"Vitamin D, parathyroid hormone, and heart failure in a Chinese elderly population","volume":"21","author":"Li","year":"2015","journal-title":"Endocr. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1681\/ASN.2015111266","article-title":"Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho","volume":"28","author":"Hum","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/bbrc.1998.8943","article-title":"Klotho protein protects against endothelial dysfunction","volume":"248","author":"Saito","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"38029","DOI":"10.1074\/jbc.M509039200","article-title":"Regulation of oxidative stress by the anti-aging hormone klotho","volume":"280","author":"Yamamoto","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"sfae255","DOI":"10.1093\/ckj\/sfae255","article-title":"The association between klotho and kidney and cardiovascular outcomes: A comprehensive systematic review and meta-analysis","volume":"17","author":"Kanbay","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/j.ajkd.2024.02.008","article-title":"Klotho and clinical outcomes in CKD: Findings from the chronic renal insufficiency cohort (CRIC) study","volume":"84","author":"Edmonston","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_75","first-page":"909","article-title":"High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients","volume":"222","author":"Voormolen","year":"2007","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/CIRCULATIONAHA.109.851873","article-title":"Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality","volume":"120","author":"Tonelli","year":"2009","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Li, J.W., Xu, C., Fan, Y., Wang, Y., and Xiao, Y.B. (2014). Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102276"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Maique, J., Flores, B., Shi, M., Shepard, S., Zhou, Z., Yan, S., Moe, O.W., and Hu, M.C. (2020). High phosphate induces and Klotho attenuates kidney epithelial senescence and fibrosis. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01273"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Shen, Z.-J., Hu, J., Shiizaki, K., Kuro-O, M., and Malter, J.S. (2016). Phosphate Induced renal fibrosis requires the prolyl isomerase Pin1. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150093"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjmed.2012.08.018","article-title":"Phosphorus and risk of renal failure in subjects with normal renal function","volume":"126","author":"Sim","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2011020175","article-title":"Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition","volume":"22","author":"Zoccali","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2015.01.009","article-title":"Serum phosphorus and progression of CKD and mortality: A meta-analysis of cohort studies","volume":"66","author":"Da","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_83","first-page":"618","article-title":"Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients","volume":"39","author":"Ortiz","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfz196","article-title":"Phosphate and bone fracture risk in chronic kidney disease patients","volume":"36","author":"Fusaro","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S8756-3282(00)00346-X","article-title":"Inorganic phosphate induces apoptosis of osteoblast-like cells in culture","volume":"27","author":"Meleti","year":"2000","journal-title":"Bone"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jcp.21283","article-title":"High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells","volume":"215","author":"Mozar","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100584","DOI":"10.1016\/j.xkme.2022.100584","article-title":"Serum Phosphorus Level Rises in US Hemodialysis Patients Over the Past Decade: A DOPPS Special Report","volume":"5","author":"Guedes","year":"2022","journal-title":"Kidney Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000245640","article-title":"Phosphate elimination in modalities of hemodialysis and peritoneal dialysis","volume":"29","author":"Kuhlmann","year":"2010","journal-title":"Blood Purif."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1681\/ASN.V451214","article-title":"Phosphate kinetics during high-flux hemodialysis","volume":"4","author":"DeSoi","year":"1993","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_92","first-page":"302","article-title":"Dynamic behavior of plasma phosphate in chronic dialysis patients","volume":"28","author":"Sugisaki","year":"1982","journal-title":"Trans. Am. Soc. Artif. Intern. Organs."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/039139888701000308","article-title":"Inorganic phosphate removal during different dialytic procedures","volume":"10","author":"Zucchelli","year":"1987","journal-title":"Int. J. Artif. Organs."},{"key":"ref_94","first-page":"108","article-title":"Phosphate kinetics in dialysis patients","volume":"6","author":"Haas","year":"1991","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_95","first-page":"M463","article-title":"Phosphate removal during hemodialysis, hemodiafiltration, and hemofiltration. A reappraisal","volume":"37","author":"Man","year":"1991","journal-title":"ASAIO Trans."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/sdi.12439","article-title":"Removal of Phosphorus by Hemodialysis","volume":"28","author":"Daugirdas","year":"2015","journal-title":"Semin. Dial."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1525-139X.2007.00304.x","article-title":"Phosphorus balance with daily dialysis","volume":"20","author":"Kooienga","year":"2007","journal-title":"Semin. Dial."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1681\/ASN.V1341046","article-title":"Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights","volume":"13","author":"Minutolo","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/hdi.12999","article-title":"Post-Dialysis Serum Phosphate Equilibrium in Hemodialysis Patients on a controlled diet and no binders","volume":"26","author":"Stremke","year":"2022","journal-title":"Hemodial. Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"F999","DOI":"10.1152\/ajprenal.00012.2016","article-title":"Peritoneal dialysis: From bench to bedside and bedside to bench","volume":"311","author":"Perl","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3747\/pdi.2014.00173","article-title":"Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Prescription","volume":"36","author":"Courivaud","year":"2016","journal-title":"Perit. Dial. Int."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1046\/j.1523-1755.2003.00310.x","article-title":"Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms","volume":"64","author":"Bammens","year":"2003","journal-title":"Kidney Int."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Debowska, M., Gomez, R., Pinto, J., Waniewski, J., and Lindholm, B. (2020). Phosphate clearance in peritoneal dialysis. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-74412-2"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Peruzzo, D., Guedes, M., Larkin, J.W., Yokoyama, G., Dos Santos, T.L., Pecoits-Filho, R., Ribeiro, S.C., Ramos, A., Barretti, P., and de Moraes, T.P. (2021). Peritoneal dialysis modality transition and impact on phosphate and potassium serum levels. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0257140"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2215\/CJN.06080809","article-title":"Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease","volume":"5","author":"Gutekunst","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_106","first-page":"266","article-title":"Dietary phosphorus intake and the risk for cardiovascular disease in the general population","volume":"18","author":"Calvo","year":"2011","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_107","first-page":"49","article-title":"Phosphate Additives in Food\u2014a Health Risk","volume":"109","author":"Ritz","year":"2012","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Dang, Z., He, Y., Xie, R., Chen, P., and Dong, F. (2025). Plant-based Diet and Chronic Kidney Disease: A Systematic Review and Meta-analysis. J. Ren. Nutr., 11.","DOI":"10.1053\/j.jrn.2025.03.002"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1168S","DOI":"10.1093\/jn\/126.suppl_4.1168S","article-title":"Changing phosphorus content of the U.S. diet: Potential for adverse effects on bone","volume":"126","author":"Calvo","year":"1996","journal-title":"J. Nutr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3109\/0886022X.2012.718724","article-title":"The adequacy of phosphorus binder prescriptions among American hemodialysis patients","volume":"34","author":"Huml","year":"2012","journal-title":"Ren Fail."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Brown-Tortorici, A.R., Narasaki, Y., You, A.S., Norris, K.C., Streja, E., Peralta, R.A., Guerrero, Y., Daza, A., Arora, R., and Lo, R. (2022). The interplay between dietary phosphorus, protein intake, and mortality in a prospective hemodialysis cohort. Nutrients, 14.","DOI":"10.3390\/nu14153070"},{"key":"ref_112","first-page":"e05674","article-title":"Re-evaluation of phosphoric acid\u2013phosphates\u2014di-, tri- and polyphosphates (E 338\u2013341, E 343, E 450\u2013452) as food additives and the safety of proposed extension of use","volume":"17","author":"Younes","year":"2019","journal-title":"EFSA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"107427","DOI":"10.1016\/j.cct.2024.107427","article-title":"Ultra-processed food intake, gut microbiome, and glucose homeostasis in mid-life adults: Background, design, and methods of a controlled feeding trial","volume":"137","author":"Capra","year":"2024","journal-title":"Contemp. Clin. Trials."},{"key":"ref_114","unstructured":"FoodNavigator-USA (2025, March 23). Until Phosphorus Gets on the USDA\u2019s Radar, Labeling Policy Won\u2019t Change\u2014NKF. Available online: https:\/\/www.foodnavigator-usa.com\/Article\/2014\/07\/17\/Until-phosphorus-gets-on-the-USDA-s-radar-labeling-policy-won-t-change-NKF\/."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.jrn.2016.09.007","article-title":"Phosphate-containing prescription medications contribute to the daily phosphate intake in a third of hemodialysis patients","volume":"27","author":"Nelson","year":"2017","journal-title":"J. Ren. Nutr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ki.2015.67","article-title":"A dearth of data: The problem of phosphorus in prescription medications","volume":"87","author":"Sherman","year":"2015","journal-title":"Kidney Int."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ki.2008.456","article-title":"A rat model of chronic kidney disease-mineral bone disorder","volume":"75","author":"Moe","year":"2009","journal-title":"Kidney Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","article-title":"Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease","volume":"6","author":"Moe","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.jrn.2009.06.002","article-title":"Soy-protein consumption and kidney-related biomarkers among type 2 diabetics: A crossover, randomized clinical trial","volume":"19","author":"Azadbakht","year":"2009","journal-title":"J. Ren. Nutr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1440-1797.2011.01464.x","article-title":"Nutritional status of vegetarians on maintenance haemodialysis","volume":"16","author":"Wu","year":"2011","journal-title":"Nephrology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.jrn.2019.11.006","article-title":"Dietary protein source and phosphate levels in patients on hemodialysis","volume":"30","author":"Young","year":"2020","journal-title":"J. Ren. Nutr."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.jrn.2020.05.002","article-title":"The International Society of Renal Nutrition and Metabolism commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI clinical practice guideline for nutrition in chronic kidney disease","volume":"31","author":"Kistler","year":"2021","journal-title":"J. Ren. Nutr."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_124","first-page":"508","article-title":"Preventing and correcting metabolic acidosis in chronic kidney disease: Implications for bone and mineral disease","volume":"61","author":"Kopple","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_125","first-page":"480","article-title":"Whole-Food Low-Protein Plant-Based Nutrition to Prevent or Slow Progression of Chronic Kidney Disease","volume":"30","author":"Goraya","year":"2020","journal-title":"J. Ren. Nutr."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Zarantonello, D., and Brunori, G. (2023). Plant-Based Diets in Preventing and Mitigating Chronic Kidney Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196137"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.jrn.2018.06.006","article-title":"Adequacy of plant-based proteins in chronic kidney disease","volume":"29","author":"Joshi","year":"2019","journal-title":"J. Ren. Nutr."},{"key":"ref_129","unstructured":"Consultant360 (2025, March 23). Dietary Modification in Renal Disease. Available online: https:\/\/www.consultant360.com\/blog\/consultant360\/nephrology\/dietary-modification-renal-disease."},{"key":"ref_130","unstructured":"Escoffier (2025, March 23). The True Costs of Processed Foods on Health and the Planet. Available online: https:\/\/www.escoffier.edu\/blog\/world-food-drink\/true-costs-processed-foods-health-planet\/#:~:text=So%20although%20processed%20food%20is,And%20agricultural%20byproducts%20are%20destroyed."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e797","DOI":"10.1016\/S2542-5196(21)00251-5","article-title":"The global and regional costs of healthy and sustainable dietary patterns: A modelling study","volume":"5","author":"Springmann","year":"2021","journal-title":"Lancet Planet. Health"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.3177\/jnsv.36.4-SupplementI_S25","article-title":"Cooking losses of minerals in foods and its nutritional significance","volume":"36","author":"Kimura","year":"1990","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"ref_133","unstructured":"Silva, A.R., Rodrigues, A.M., and Lima, M.L. (2021). Do plant-based consumers spend more on food?. Front. Nutr., 8."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e2332106","DOI":"10.1001\/jamanetworkopen.2023.32106","article-title":"Vegan diet and food costs among adults with overweight: A secondary analysis of a randomized clinical trial","volume":"6","author":"Kahleova","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_135","unstructured":"GFI (2025, March 23). Reducing the Price of Alternative Proteins. Available online: https:\/\/gfi.org\/reducing-the-price-of-alternative-proteins\/."},{"key":"ref_136","unstructured":"(2025, March 23). Food & Wine. Why Going Vegetarian Is a Recipe for a Cheaper Grocery Bill. Available online: https:\/\/www.foodandwine.com\/vegetarian-cheapest-groceries-report-11685113."},{"key":"ref_137","unstructured":"The Guardian (2025, March 23). \u201cDon\u2019t Be Scared of Beans\u201c: How Readers are Handling US Grocery Inflation. Available online: https:\/\/www.theguardian.com\/environment\/article\/2024\/aug\/28\/inflation-groceries-tips."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1051-2276(01)38751-4","article-title":"Demineralization of a wide variety of foods for the renal patient","volume":"11","author":"Jones","year":"2001","journal-title":"J. Ren. Nutr."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Naber, T., and Purohit, S. (2021). Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease. Nutrients, 13.","DOI":"10.20944\/preprints202106.0233.v1"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Noce, A., Marrone, G., Wilson Jones, G., Di Lauro, M., Pietroboni Zaitseva, A., Ramadori, L., Celotto, R., Mitterhofer, A.P., and Di Daniele, N. (2021). Nutritional Approaches for the Management of Metabolic Acidosis in Chronic Kidney Disease. Nutrients, 13.","DOI":"10.3390\/nu13082534"},{"key":"ref_141","first-page":"22","article-title":"Caring for Patients with Advanced Chronic Kidney Disease: Dietary Considerations","volume":"38","author":"Bellizzi","year":"2023","journal-title":"Nutr. Clin. Pract."},{"key":"ref_142","unstructured":"(2025, March 24). US-DOPPS Practice Monitor. Available online: http:\/\/www.dopps.org\/DPM."},{"key":"ref_143","unstructured":"Fresenius Medical Care North America (2011). PhosLo\u00ae Gelcaps (Calcium Acetate): 667 mg [Prescribing Information], Fresenius Medical Care North America."},{"key":"ref_144","unstructured":"Fresenius Medical Care North America (2013). VELPHORO \u00ae (Sucroferric Oxyhydroxide) [Prescribing Information], Fresenius Medical Care North America."},{"key":"ref_145","unstructured":"Shire US Inc. (2016). FOSRENAL\u00ae (Lanthanum Carbonate) [Prescribing Information], Shire US Inc."},{"key":"ref_146","unstructured":"Keryx Biopharmaceuticals Inc. (2017). AURYXIA\u00ae (Ferric Citrate) Tablets [Prescribing Information], Keryx Biopharmaceuticals Inc."},{"key":"ref_147","unstructured":"Genzyme Corp. (2020). RENVELA\u00ae (Sevelamer Carbonate) [80Prescribing Information], Genzyme Corp."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199102213240804","article-title":"Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease","volume":"324","author":"Salusky","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/bmj.1.6120.1101","article-title":"Aluminium toxicity during regular haemodialysis","volume":"1","author":"Elliott","year":"1978","journal-title":"BMJ"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(79)90883-3","article-title":"Fracturing dialysis osteodystrophy and dialysis encephalopathy: An epidemiological survey","volume":"1","author":"Parkinson","year":"1979","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation (2003). K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis., 42, S1\u2013S201.","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"ref_153","first-page":"111","article-title":"Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients","volume":"45","author":"Janssen","year":"1996","journal-title":"Clin. Nephrol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","article-title":"Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials","volume":"54","author":"Navaneethan","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/ndt\/gfm421","article-title":"Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients","volume":"22","author":"Tonelli","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","article-title":"Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets","volume":"81","author":"Spiegel","year":"2012","journal-title":"Kidney Int."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: A randomized study","volume":"7","author":"Bellasi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: Results of an open-label 24-monthandomized clinical trial","volume":"62","author":"Molony","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Zheng, C., Liu, J., Wang, T., Hu, H., and Chen, Y. (2025). A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials. Sci. Rep., 15.","DOI":"10.1038\/s41598-024-84942-8"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-014-0215-7","article-title":"Sevelamer carbonate: A review in hyperphosphataemia in adults with chronic kidney disease","volume":"74","author":"Perry","year":"2014","journal-title":"Drugs"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.2215\/CJN.05880809","article-title":"Ten-year experience with sevelamer and calcium salts as phosphate binders","volume":"5","author":"Raggi","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2016.164","article-title":"The role of phosphate in kidney disease","volume":"13","author":"Vervloet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40265-019-01118-9","article-title":"Does the administration of sevelamer or nicotinamide modify uremic toxins or endotoxemia in chronic hemodialysis patients?","volume":"79","author":"Lenglet","year":"2019","journal-title":"Drugs"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/ndt\/gfn162","article-title":"Sevelamer","volume":"23","author":"Wrong","year":"2008","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1592\/phco.29.5.554","article-title":"Comparison of sevelamer hydrochloride and sevelamer carbonate: Risk of metabolic acidosis and clinical implications","volume":"29","author":"Pai","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5414\/CNP68386","article-title":"A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis","volume":"68","author":"Delmez","year":"2007","journal-title":"Clin. Nephrol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial. Int."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003495-200868010-00006","article-title":"Sevelamer hydrochloride: A review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis","volume":"68","author":"Goldsmith","year":"2008","journal-title":"Drugs"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3182999d8d","article-title":"Sevelamer Crystals in the Gastrointestinal Tract (GIT) A New Entity Associated with Mucosal Injury","volume":"37","author":"Swanson","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Elkalashy, A., Rainwater, R.R., Ali, U., Elbahnasawy, E., Singh, M., and Karakala, N. (2025). Gastrointestinal mucosal cell injury caused by sevelamer crystals\u2014Case series and literature review. J. Renal. Nutr.","DOI":"10.1053\/j.jrn.2025.01.008"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1523-1755.2002.00459.x","article-title":"Bile acid binding to sevelamer HCl","volume":"62","author":"Braunlin","year":"2002","journal-title":"Kidney Int."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","article-title":"Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients","volume":"10","author":"Burke","year":"2003","journal-title":"Adv. Ren. Replace. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.ajkd.2011.12.001","article-title":"Potential interaction between sevelamer and fat-soluble vitamins: A hypothesis","volume":"59","author":"Susantitaphong","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Vemuri, N., Michelis, M.F., and Matalon, A. (2011). Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: A multicenter open-label study. BMC Nephrol., 12.","DOI":"10.1186\/1471-2369-12-49"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5414\/CN107330","article-title":"Efficacy and safety of lanthanum carbonate in German patients on dialysis","volume":"78","author":"Dellanna","year":"2012","journal-title":"Clin. Nephrol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s12325-013-0077-5","article-title":"The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease","volume":"30","author":"Wilson","year":"2013","journal-title":"Adv. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CN108269","article-title":"Effcacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: A randomized trial","volume":"82","author":"Takahara","year":"2014","journal-title":"Clin. Nephrol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN107257","article-title":"Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: A crossover study","volume":"78","author":"Toida","year":"2012","journal-title":"Clin. Nephrol."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wen, J., Li, Z., and Fan, J. (2013). Efficacy and safety of lanthanum carbonate on chronic kidney disease mineral and bone disorder in dialysis patients: A systematic review. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-226"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1523-1755.2005.00171.x","article-title":"Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration","volume":"67","author":"Lacour","year":"2005","journal-title":"Kidney Int."},{"key":"ref_184","first-page":"286","article-title":"Lanthanum carbon- ate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis","volume":"71","author":"Hutchison","year":"2009","journal-title":"Clin. Nephrol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol. Dial. Transplant"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/nep.12864","article-title":"Lanthanum carbonate: Safety data after 10 years","volume":"21","author":"Hutchison","year":"2016","journal-title":"Nephrology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","article-title":"Collaborative Study Group. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results from Prespecified Analyses of a Randomized Clinical Trial","volume":"66","author":"Lewis","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40620-016-0266-9","article-title":"Phosphate binders in chronic kidney disease: A systematic review of recent data","volume":"29","author":"Floege","year":"2016","journal-title":"J. Nephrol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1389200216666150206124424","article-title":"Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide","volume":"15","author":"Cozzolino","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/ndt\/gfy127","article-title":"Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients","volume":"34","author":"Ketteler","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_196","first-page":"1330","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000505432","article-title":"Chronic therapy with sucroferric oxyhydroxide does not affect iron and anemia markers in dialysis patients","volume":"49","author":"Lioulios","year":"2020","journal-title":"Blood Purif."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2011121213","article-title":"Npt2b deletion attenuates hyperphosphatemia associated with CKD","volume":"23","author":"Schiavi","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2215\/CJN.01470307","article-title":"Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients","volume":"2","author":"Mehling","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial","volume":"30","author":"Ix","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ndt\/gfac206","article-title":"Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial","volume":"38","author":"Ketteler","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.jrn.2024.07.003","article-title":"Tenapanor: A phosphate absorption inhibitor for the management of hyperphosphatemia in patients with kidney failure","volume":"35","author":"Gallant","year":"2025","journal-title":"J. Ren. Nutr."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"Pergola","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_205","unstructured":"(2025, March 24). Clinical Data Supporting XPHOZAH. Available online: https:\/\/ir.ardelyx.com\/news-releases\/news-release-details\/fda-approves-xphozahr-tenapanor-first-class-phosphate-absorption#:~:text=FDA%20approval%20of%20XPHOZAH%20is,met%20their%20primary%20and%20key."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41100-021-00322-2","article-title":"Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients","volume":"7","author":"Nagano","year":"2021","journal-title":"Ren. Replace. Ther."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"100437","DOI":"10.1016\/j.xkme.2022.100437","article-title":"The Impact of Phosphorus Management Today on Quality of Life: Patient Perspectives","volume":"4","author":"Forfang","year":"2022","journal-title":"Kidney Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/j.ajkd.2020.10.008","article-title":"Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients on Maintenance Hemodialysis","volume":"77","author":"Edmonston","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1681\/ASN.2021010027","article-title":"In Search of the Optimal Target for Phosphate Control: Episode 1","volume":"32","author":"Wald","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2017.12.007","article-title":"Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?","volume":"72","author":"Greg","year":"2018","journal-title":"Am. J. Kidney Dis."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/9\/1587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:27:14Z","timestamp":1760030834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/9\/1587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":211,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["nu17091587"],"URL":"https:\/\/doi.org\/10.3390\/nu17091587","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}